Top 10 Asian Companies To Watch In Right Now

Top 10 Asian Companies To Watch I n Right Now: Coronado Biosciences Inc (CNDO)

Coronado Biosciences, Inc., incorporated on June 28, 2006, is a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the treatment of autoimmune diseases and cancer. The Companys two principal pharmaceutical product candidates in clinical development include Trichuris suis ova or CNDO-201 (TSO) a biologic comprising of the microscopic eggs of the porcine whipworm, for the treatment of autoimmune diseases, such as Crohns disease (Crohns), ulcerative colitis (UC) and multiple sclerosis (MS), and CNDO-109, a compound that activates natural killer (NK) cells of the immune system to seek and destroy cancer cells, for the treatment of acute myeloid leukemia (AML). In January 2011, the Company acquired the OvaMed GmbH License.

TSO

TSO is the microscopic eggs of a parasitic helminth, or worm, that is found in pigs. In September 2011, the Company filed an Investigational New Drug Application (IND) with t he United States Food and Drug Administration (FDA) and it initiated a single dose, dose escalation study in patients with Crohns in February 2012. The Phase 1 clinical trial was a multi-center, sequential dose-escalation, double-blind, placebo-controlled study, the primary objective of which was to evaluate the safety and tolerability of TSO. The trial enrolled 36 patients with Crohns ranging in age from 20 to 54 with an equal distribution of male and female patients in three single dose cohorts of orally administered 500, 2500 and 7500 ova. Each cohort had 12 patients, with nine patients receiving TSO and three receiving placebo.

CNDO-109

CNDO-109 is a lysate (disrupted CTV-1 cells, cell membrane fragments, cell proteins and other cellular components) that activates donor NK cells. CTV-1 is a leukemic cell line recently re-classified as a T-cell acute lymphocytic leukemia (ALL). The Company has worldwide rights to develop ! and commercialize CNDO-109 activated NK cells for the treatment of cancer fro! m UCLB. In February 2012, the Company submitted an IND for the CNDO-109 activated NK cell product in the United States. The treatment of patients with CNDO-109 activated NK cells involves several steps. The activated NK cells are infused into the patient after resting NK cells are incubated with CNDO-109 for at least eight hours. Preparation of CNDO-109 activated NK cells takes about 24 hours from start to finish.

The Company competes with Centocor Ortho Biotech Inc.s Remicade , UCB S.A.s Cimzia, Abbott Laboratories Humira, Biogen Idecs Avonex, Bayer Healthcare Pharmaceuticals Betaseron, Teva Pharmaceuticals Industries, Ltd.s Copaxone and Novartis AGs Gilenya.

Advisors' Opinion:

• [By CRWE]

  Coronado Biosciences, Inc. (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the treatment of autoimmune diseases and cancer, reported that it has filed a registration statement with the Securities and Exchange Commission for a proposed public offering of 2,000,000 shares of its common stock. All shares proposed to be included in the offering will be sold by the company.

• [By Grace L. Williams]

  Honorable mentions go out to Coronado Biosciences (CNDO), after its CEO Harlan Weisman and Jay Lobell, a longtime director, joined forces and bought 20,000 shares for $152,100; and to Anacor Pharmaceuticals (ANAC) after CFO Geoffrey Parker bought 33,000 shares for $224,300. InsiderScore noted that Parkers purchase was his largest to date and called it a compelling positive event.

source from Top Penny Stocks For 2015:http://www.topstocksforum.com/top-10-asian-companies-to-watch-in-right-now-2.html